Off-the-shelf CAR-T produces complete remission in patient with advanced kidney cancer
Kidney cancer is one of the most common types of cancer, with approximately 50,000 patients diagnosed in the United States each year. That’s why researchers developed CTX130 (CRISPR Therapeutics), which is an allogeneic, CRISPR/Cas9-modified CAR-T therapy that targets CD70, an antigen known to be expressed by certain solid tumors and hematological malignancies. This treatment controlled […]